Description

Ravulizumab is a monoclonal antibody used in the treatment of certain complement-mediated diseases, such as paroxysmal nocturnal hemoglobinuria (PNH). It works by inhibiting the complement cascade, thereby reducing hemolysis and associated symptoms in affected patients.

Interpreter Notes

Interpreters should be aware that ravulizumab may be referred to by its brand name in some contexts, which could vary regionally. It is important to maintain a formal register when discussing this medication and to avoid colloquial terms that may not be understood in a clinical setting. Always stick to the glossary term to ensure clarity.

Example Sentences

EN: The patient was prescribed ravulizumab to manage their symptoms of paroxysmal nocturnal hemoglobinuria.

ES: Se le recetó ravulizumab al paciente para manejar sus síntomas de hemoglobinuria paroxística nocturna.

Common Interpreter Mistakes

Confusing ravulizumab with similar medications; using informal language when discussing the drug; mispronouncing the term as if it were a common word.